These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clozapine screening: white bloodcell counts no longer sufficient].
    Author: Cohen D, Clozapinepluswerkgroep.
    Journal: Tijdschr Psychiatr; 2010; 52(11):785-90. PubMed ID: 21064021.
    Abstract:
    Clozapine is an effective antipsychotic drug for the treatment of therapy-resistant schizophrenia. Mandatory screening of white blood cells is a safety measure for the early detection of agranulocytosis caused by treatment with clozapine. However, so far, there is no standard screening for two other potentially lethal side-effects, namely diabetic ketoacidosis and gastro-intestinal hypomotility. The current situation is weighed up on the basis of a comparison of the chances that these side-effects can occur and cause death. The conclusion is that weekly or monthly screening should be carried out for all these side-effects.
    [Abstract] [Full Text] [Related] [New Search]